Jump to content

Evinacumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 18:32, 19 November 2015 (Identifier not assigned: use =none (CAS RN, ChemSpider, ATC) (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Evinacumab
Monoclonal antibody
Type?
SourceHuman
Targetangiopoietin 3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6480H9992N1716O2042S46
Molar mass146.1 kDa g·mol−1

Evinacumab is a monoclonal antibody designed for the treatment of dyslipidemia.[1]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Evinacumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Evinacumab&oldid=691418818"